MX387296B - Proliferacion ex vivo de celulas epiteliales. - Google Patents

Proliferacion ex vivo de celulas epiteliales.

Info

Publication number
MX387296B
MX387296B MX2017012206A MX2017012206A MX387296B MX 387296 B MX387296 B MX 387296B MX 2017012206 A MX2017012206 A MX 2017012206A MX 2017012206 A MX2017012206 A MX 2017012206A MX 387296 B MX387296 B MX 387296B
Authority
MX
Mexico
Prior art keywords
epithelial cells
vivo proliferation
proliferation
vivo
compositions
Prior art date
Application number
MX2017012206A
Other languages
English (en)
Other versions
MX2017012206A (es
Inventor
Chengkang Zhang
Original Assignee
Propagenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Propagenix Inc filed Critical Propagenix Inc
Publication of MX2017012206A publication Critical patent/MX2017012206A/es
Publication of MX387296B publication Critical patent/MX387296B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0629—Keratinocytes; Whole skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0683—Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0688—Cells from the lungs or the respiratory tract
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C12N2500/14—Calcium; Ca chelators; Calcitonin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/99—Serum-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a métodos y composiciones para la proliferación y expansión ex vivo de células epiteliales.
MX2017012206A 2015-04-03 2016-03-31 Proliferacion ex vivo de celulas epiteliales. MX387296B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562142851P 2015-04-03 2015-04-03
US201562217406P 2015-09-11 2015-09-11
US201662294896P 2016-02-12 2016-02-12
PCT/US2016/025396 WO2016161192A1 (en) 2015-04-03 2016-03-31 Ex vivo proliferation of epithelial cells

Publications (2)

Publication Number Publication Date
MX2017012206A MX2017012206A (es) 2018-01-24
MX387296B true MX387296B (es) 2025-03-11

Family

ID=55806770

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012206A MX387296B (es) 2015-04-03 2016-03-31 Proliferacion ex vivo de celulas epiteliales.

Country Status (12)

Country Link
US (7) US9790471B2 (es)
EP (2) EP3822339A1 (es)
JP (2) JP6964068B2 (es)
KR (1) KR102598772B1 (es)
CN (1) CN107636149A (es)
AU (1) AU2016243750B2 (es)
CA (1) CA2981708C (es)
DK (1) DK3277799T3 (es)
IL (1) IL254588B (es)
MX (1) MX387296B (es)
SG (2) SG11201707970XA (es)
WO (1) WO2016161192A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016243750B2 (en) 2015-04-03 2022-02-03 Propagenix Inc. Ex vivo proliferation of epithelial cells
US10100285B2 (en) 2015-04-03 2018-10-16 Propagenix Inc. Ex vivo proliferation of epithelial cells
EP3347450B1 (en) 2015-09-11 2021-03-17 Propagenix Inc. Ex vivo proliferation of epithelial cells
CN110914406A (zh) * 2017-06-30 2020-03-24 思特科技公司 从尿液细胞直接逆分化为角质形成细胞干细胞的方法及利用逆分化的角质形成细胞干细胞的用于促进皮肤再生的组合物的制备方法
WO2019180269A1 (en) * 2018-03-23 2019-09-26 Cytoo Alk5 inhibitors as skeletal muscle hypertrophy inducers
HU231285B1 (hu) 2018-04-18 2022-08-28 Printnet Kereskedelmi És Szolgáltató Kft. A miozin-2-izoformákat szelektíven gátló, gyógyászatilag hatásos vegyületek
CA3107502A1 (en) 2018-08-20 2020-02-27 Chengkang ZHANG Epithelial cell spheroids
KR20200032830A (ko) * 2018-09-19 2020-03-27 메디칸(주) 자가 줄기세포의 자가 배양 방법 및 장치
KR20210072033A (ko) 2018-10-03 2021-06-16 스템바이오시스, 인크. 양수 세포-유래된 세포외 매트릭스 및 그의 용도
US11047849B2 (en) * 2018-10-17 2021-06-29 Mandom Corporation Method for observing sebaceous gland and use thereof
CN109294972A (zh) * 2018-10-17 2019-02-01 南京农业大学 一种羔羊小肠上皮细胞体外培养方法
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
KR102639023B1 (ko) 2019-02-21 2024-02-20 스템바이오시스, 인크. 양수 세포-유래 ecm 상에서 심근세포 성숙을 위한 방법, 세포 구조, 및 약물 화합물의 심장 독성 및 전부정맥 스크리닝을 위한 용도
CA3130930A1 (en) * 2019-03-19 2020-09-24 Kyuson Yun Methods and systems for evaluation of cell samples
EP4041252A4 (en) * 2019-09-09 2023-11-01 The Regents Of The University Of Michigan DEVELOPMENT OF EMBRYO-LIKE TISSUE FROM STEM CELLS
CN113249325B (zh) * 2020-02-11 2023-02-17 合肥中科普瑞昇生物医药科技有限公司 食管鳞癌原代细胞的培养基及培养方法
WO2021203911A1 (zh) * 2020-04-09 2021-10-14 中国医学科学院阜外医院 用于心肌细胞冻存的组合物
CN116615211A (zh) * 2020-10-19 2023-08-18 特拉哈斯霍默医学研究基础设施和服务有限公司 尿源性上皮细胞培养物、由此得到的肾球状体以及其制备和使用方法
US12344862B2 (en) * 2020-11-03 2025-07-01 Korea Research Institute Of Bioscience And Biotechnology Human intestinal epithelium model and method for preparing same
CN115873797B (zh) * 2021-09-29 2024-08-13 北京干细胞与再生医学研究院 一种视网膜色素上皮细胞的扩增培养基及培养方法
CN114181889B (zh) * 2021-11-24 2023-10-10 中国人民解放军总医院 一种原代汗腺细胞条件培养基及原代汗腺细胞培养方法
US20250043250A1 (en) * 2021-12-16 2025-02-06 Stemcell Technologies Canada Inc. Compositions and methods for expanding keratinocytes
CN117018032A (zh) * 2022-05-10 2023-11-10 上海赛立维生物科技有限公司 包含骨骼肌前体样细胞的生物制剂及其制备方法和应用
CN117503800B (zh) * 2024-01-04 2024-04-05 北京益华生物科技有限公司 一种胃黏膜上皮细胞提取液及其制备方法与应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3716907A1 (de) 1987-05-20 1988-12-01 Battelle Institut E V Verfahren zur vermehrung von epithelialzellen
CA1335572C (en) 1988-05-23 1995-05-16 Yoon Sang Cho-Chung Derivatives of cyclic amp as treatment for cancer
US6692961B1 (en) * 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
US7326570B2 (en) 2000-06-16 2008-02-05 The Regents Of The University Of California Induction of tubular morphogenesis using pleiotrophin
US7199147B2 (en) 2001-06-12 2007-04-03 Dainippon Sumitomo Pharma Co., Ltd. Rho kinase inhibitors
CA2472619A1 (en) 2002-01-10 2003-07-24 Bayer Corporation Fused pyrimidine derivates as rho-kinase inhibitors
MXPA04007191A (es) 2002-01-23 2005-03-31 Bayer Pharmaceuticals Corp Derivados de pirimidina como inhibidores de rho-quinasa.
MXPA04007196A (es) 2002-01-23 2005-06-08 Bayer Pharmaceuticals Corp Inhibidores de rho-quinasa.
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
AU2003217350A1 (en) 2002-02-08 2003-09-02 University Of Chile Proliferated cell lines and uses thereof
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
WO2003082808A1 (en) 2002-04-03 2003-10-09 Sumitomo Pharmaceuticals Company, Limited. Benzamide derivatives
US20040058392A1 (en) 2002-09-17 2004-03-25 Kylix B.V. Use of novel stem cell markers for isolation of intestinal stem cells, and use of the intestinal stem cells thus obtained for the preparation of a therapeutical composition
AU2003278088A1 (en) 2002-10-28 2004-05-25 Bayer Healthcare Ag Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
US20070010008A1 (en) * 2005-06-29 2007-01-11 Tissuetech, Inc. Ex vivo expansion of primary animal cells
WO2004112719A2 (en) 2003-06-19 2004-12-29 Smithkline Beecham Corporation Chemical compounds
CA2528483C (en) 2003-06-23 2012-04-10 Geron Corporation Compositions and methods for increasing telomerase activity
EP1644365A2 (en) 2003-07-02 2006-04-12 Biofocus Discovery Ltd Pyrazine and pyridine derivatives as rho kinase inhibitors
US8252591B2 (en) 2004-05-07 2012-08-28 Whitehead Institute For Biomedical Research Hormone responsive tissue culture system and uses thereof
WO2006090882A1 (ja) 2005-02-23 2006-08-31 Foundation For Biomedical Research And Innovation 血管内皮前駆細胞の生体外増幅方法
CN103361302A (zh) 2005-03-31 2013-10-23 斯丹姆涅恩有限公司 从高度纯化来自羊膜的细胞群获得的细胞裂解产物的组合物
CA2621161A1 (en) 2005-09-08 2007-03-15 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Methods for promoting stem cell proliferation and survival
US7989204B2 (en) 2006-04-28 2011-08-02 Viacyte, Inc. Hepatocyte lineage cells
WO2008009642A1 (en) 2006-07-17 2008-01-24 Novozymes A/S Cell culture media
EP2022848A1 (en) 2007-08-10 2009-02-11 Hubrecht Institut A method for identifying, expanding, and removing adult stem cells and cancer stem cells
US9752124B2 (en) * 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
PL3441458T3 (pl) 2009-02-03 2023-11-06 Koninklijke Nederlandse Akademie Van Wetenschappen Podłoże do hodowli nabłonkowych komórek macierzystych i organoidów zawierających wspomniane komórki macierzyste
GB201111244D0 (en) 2011-06-30 2011-08-17 Konink Nl Akademie Van Wetenschappen Knaw Culture media for stem cells
US8476081B2 (en) 2009-09-21 2013-07-02 Janssen Pharmaceutica Nv Assay for evaluating affinity and specificity of ligand-albumin binding
US9708582B2 (en) 2009-10-13 2017-07-18 Stemcell Technologies Inc. Method of differentiating stem cells
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012065067A2 (en) 2010-11-12 2012-05-18 Georgetown University Immortalization of epithelial cells and methods of use
JPWO2012173207A1 (ja) 2011-06-14 2015-02-23 独立行政法人理化学研究所 網膜細胞への分化誘導方法
JP6238445B2 (ja) 2011-10-27 2017-11-29 国立大学法人 東京医科歯科大学 大腸上皮幹細胞の単離・培養技術と、これを用いた大腸上皮移植技術
EP2802647B1 (en) 2012-01-13 2020-10-28 The General Hospital Corporation Isolated human lung progenitor cells and uses thereof
US9850463B2 (en) 2012-02-01 2017-12-26 The Regents Of The University Of California Methods of culturing retinal pigmented epithelium cells, including xeno-free production, RPE enrichment, and cryopreservation
WO2013184809A1 (en) 2012-06-05 2013-12-12 The Regents Of The University Of California Methods and compositions for the rapid production of retinal pigmented epithelial cells from pluripotent cells
WO2014078414A1 (en) 2012-11-13 2014-05-22 Joseph Wu Chemically defined production of cardiomyocytes from pluripotent stem cells
US9533013B2 (en) 2013-03-13 2017-01-03 University Of North Carolina At Chapel Hill Method of treating pancreatic and liver conditions by endoscopic-mediated (or laparoscopic-mediated) transplantation of stem cells into/onto bile duct walls of particular regions of the biliary tree
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
CA2906643A1 (en) * 2013-03-15 2014-09-25 The Jackson Laboratory Isolation of non-embryonic stem cells and uses thereof
WO2014165663A1 (en) * 2013-04-03 2014-10-09 Cellular Dynamics International, Inc. Methods and compositions for culturing endoderm progenitor cells in suspension
WO2014162040A1 (en) 2013-04-03 2014-10-09 Tampereen Yliopisto Methods and media for differentiating eye cells
AU2016243750B2 (en) 2015-04-03 2022-02-03 Propagenix Inc. Ex vivo proliferation of epithelial cells
US10100285B2 (en) 2015-04-03 2018-10-16 Propagenix Inc. Ex vivo proliferation of epithelial cells
EP3347450B1 (en) 2015-09-11 2021-03-17 Propagenix Inc. Ex vivo proliferation of epithelial cells

Also Published As

Publication number Publication date
CN107636149A (zh) 2018-01-26
US20180208899A1 (en) 2018-07-26
MX2017012206A (es) 2018-01-24
IL254588A0 (en) 2017-11-30
HK1249919A1 (zh) 2018-11-16
US10119121B2 (en) 2018-11-06
SG10201902872YA (en) 2019-04-29
US11680246B2 (en) 2023-06-20
US20230416686A1 (en) 2023-12-28
US10711251B2 (en) 2020-07-14
US9963680B2 (en) 2018-05-08
JP2018512890A (ja) 2018-05-24
DK3277799T3 (en) 2020-12-14
US20170029780A1 (en) 2017-02-02
US10711250B2 (en) 2020-07-14
SG11201707970XA (en) 2017-10-30
AU2016243750B2 (en) 2022-02-03
JP6964068B2 (ja) 2021-11-10
EP3277799A1 (en) 2018-02-07
EP3277799B1 (en) 2020-09-23
WO2016161192A1 (en) 2016-10-06
CA2981708C (en) 2024-09-10
KR20170134634A (ko) 2017-12-06
US20180208900A1 (en) 2018-07-26
AU2016243750A1 (en) 2017-10-05
KR102598772B1 (ko) 2023-11-03
US20170029779A1 (en) 2017-02-02
JP2020120686A (ja) 2020-08-13
US20210032602A1 (en) 2021-02-04
EP3822339A1 (en) 2021-05-19
CA2981708A1 (en) 2016-10-06
IL254588B (en) 2020-07-30
US20180002669A1 (en) 2018-01-04
US9790471B2 (en) 2017-10-17

Similar Documents

Publication Publication Date Title
MX387296B (es) Proliferacion ex vivo de celulas epiteliales.
ZA201904258B (en) Compositions and methods for epithelial stem cell expansion and culture
PH12018500647A1 (en) Affinity-oligonucleotide conjugates and uses thereof
ZA201806132B (en) Methods and compositions relating to hematopoietic stem cell expansion
CO2017009514A2 (es) Derivados de sobetiroma
PL4074331T3 (pl) Kompozycje i sposoby internalizacji enzymów
PL3368658T3 (pl) Namnażanie komórek T gamma delta rezydujących w tkankach nie-krwiotwórczych i zastosowania tych komórek
UY35510A (es) ?composiciones y métodos para mejorar la estabilidad microbiana?.
PL2978419T3 (pl) Kompozycje do zwiększania żywotności komórek i metody ich stosowania
PH12015502048A1 (en) Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
TR201908418T4 (tr) Sürdürülebilir immünoterapi için yöntem ve kompozisyonlar.
MX2015011281A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
MX390739B (es) Composicion de hueso comprimido y metodo para usar la misma.
TW201612308A (en) Collector architecture layout design
CL2016000351A1 (es) Método para la cuantificación de actinio-227 en composiciones de radio-223.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
EA201890439A1 (ru) ИММУНООНКОЛОГИЧЕСКАЯ МЕЗОДЕРМАЛЬНАЯ КЛЕТКА-ПРЕДШЕСТВЕННИК (ioMP-КЛЕТКА)
UY34543A (es) Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica.
MX2015016603A (es) Composiciones de corticosteroides.
ECSP18050673A (es) Formulaciones de giberelina en solución concentrada
MX2015012523A (es) Metodos para elaborar composiciones antineoplasicas.
UY34457A (es) Composición de Nitazoxanida mejorada y proceso para prepararla
IES20140280A2 (en) Human targets II
CU20150136A7 (es) Derivados de oxopiridona sustituida empleados en trastornos cardiovasculares
JOP20170121A1 (ar) مصدر للماء في تركيبة للاستخدام الموضعي